Harris Oakmark's second-quarter 2026 investor letter for its “Oakmark Global Fund” has spotlighted an intriguing new addition to its portfolio: The Cooper Companies, Inc. This medical device company, trading under the NASDAQ ticker COO, has captured the fund's attention following a recent market decline. Despite the Oakmark Global Fund’s overall performance trailing its benchmark, the MSCI World Index, with a 7.89% return compared to the benchmark's 13.76%, the fund's focus remains on identifying long-term capital appreciation opportunities. Its investment philosophy emphasizes evaluating companies based on their competitive strengths, potential for sustained cash flow, and intrinsic valuation, rather than short-term market predictions. The decision to invest in Cooper Companies stems from a belief that the current market pullback presents an attractive entry point for a company with solid fundamentals and significant growth prospects in the specialized medical device sector.

Oakmark Global Fund Adds Cooper Companies to Portfolio Amidst Market Correction

On Wednesday, July 15, 2026, Harris Oakmark, through its Oakmark Global Fund, officially announced its acquisition of shares in The Cooper Companies, Inc. (NASDAQ: COO), a prominent player in the medical device industry. The announcement, detailed in the fund's second-quarter investor letter, highlights this new position as a strategic move. Cooper Companies, with its dual focus on CooperVision, a contact lens manufacturer, and CooperSurgical, specializing in women's health products, closed at $68.51 per share on July 14, 2026. Despite a 7.35% increase over the past month, the company's shares experienced a 3.95% decline over the preceding 52 weeks, bringing its market capitalization to $13.36 billion. This dip in share price, according to Oakmark Global Fund, created a compelling valuation for initiating an investment. The fund's rationale centers on the contact lens market's oligopolistic structure, characterized by high barriers to entry, consistent revenue streams, and a history of positive pricing trends that support mid-single-digit growth. Cooper's impressive record of gaining market share, particularly through its leadership in specialty lenses and innovative private-label approach, further reinforces Oakmark's confidence. The fund also noted positive developments in Cooper's efforts to enhance free cash flow conversion, accelerate growth, and refine its product portfolio. Compared to its industry peers, private market transactions, and its own historical trading patterns, Cooper Companies currently trades at a substantial discount, making it an attractive prospect for long-term investors seeking intrinsic value.

This strategic investment by Oakmark Global Fund underscores the importance of thorough fundamental analysis in volatile market conditions. While the broader market, particularly the medical technology sector, has seen some corrections, opportunities often arise for discerning investors. Cooper Companies, with its robust business model and strategic initiatives, exemplifies such an opportunity. For investors, this move by a respected fund like Oakmark serves as a reminder to look beyond short-term fluctuations and focus on companies with strong competitive advantages and clear pathways for future growth, especially when market pullbacks offer more favorable entry points.